Cargando…

Anti-inflammatory treatments for stroke: from bench to bedside

So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Drieu, Antoine, Levard, Damien, Vivien, Denis, Rubio, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066814/
https://www.ncbi.nlm.nih.gov/pubmed/30083232
http://dx.doi.org/10.1177/1756286418789854
_version_ 1783343037303226368
author Drieu, Antoine
Levard, Damien
Vivien, Denis
Rubio, Marina
author_facet Drieu, Antoine
Levard, Damien
Vivien, Denis
Rubio, Marina
author_sort Drieu, Antoine
collection PubMed
description So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators.
format Online
Article
Text
id pubmed-6066814
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60668142018-08-06 Anti-inflammatory treatments for stroke: from bench to bedside Drieu, Antoine Levard, Damien Vivien, Denis Rubio, Marina Ther Adv Neurol Disord Review So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators. SAGE Publications 2018-07-30 /pmc/articles/PMC6066814/ /pubmed/30083232 http://dx.doi.org/10.1177/1756286418789854 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Drieu, Antoine
Levard, Damien
Vivien, Denis
Rubio, Marina
Anti-inflammatory treatments for stroke: from bench to bedside
title Anti-inflammatory treatments for stroke: from bench to bedside
title_full Anti-inflammatory treatments for stroke: from bench to bedside
title_fullStr Anti-inflammatory treatments for stroke: from bench to bedside
title_full_unstemmed Anti-inflammatory treatments for stroke: from bench to bedside
title_short Anti-inflammatory treatments for stroke: from bench to bedside
title_sort anti-inflammatory treatments for stroke: from bench to bedside
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066814/
https://www.ncbi.nlm.nih.gov/pubmed/30083232
http://dx.doi.org/10.1177/1756286418789854
work_keys_str_mv AT drieuantoine antiinflammatorytreatmentsforstrokefrombenchtobedside
AT levarddamien antiinflammatorytreatmentsforstrokefrombenchtobedside
AT viviendenis antiinflammatorytreatmentsforstrokefrombenchtobedside
AT rubiomarina antiinflammatorytreatmentsforstrokefrombenchtobedside